Domestic pharmaceutical companies have poured out 42 generics of Baraclude just in this year
Domestic pharmaceutical companies have shown interests in type B hepatitis treatments.
According to the Ministry of Food and Drug Safety, generics of ‘Baraclude (entecavir),’ which were first introduced by BMS Korea in Korea in 2006, are poured out since the last year.
While 50 products were ap...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
